抗药性
医学
逆转录酶
艾滋病毒耐药性
整合酶
人口
传输(电信)
病毒学
药品
整合酶抑制剂
人类免疫缺陷病毒(HIV)
抗逆转录病毒疗法
内科学
病毒载量
生物
药理学
环境卫生
聚合酶链反应
基因
遗传学
电气工程
工程类
作者
Xujian Cao,Jing Cao,Hui Qi,Weiwei Yu,Ziwei Zeng,Yongquan Peng,Min Wang
标识
DOI:10.1089/aid.2022.0077
摘要
At present, research on the prevalence of primary drug resistance (PDR) in Hunan Province is limited. Therefore, we explored the current status of HIV-1 PDR in Hunan to provide a basis for antiretroviral therapy (ART) and a theoretical foundation for prevention and control of the HIV/AIDS epidemic. Three hundred seventy newly diagnosed HIV-1-infected individuals who had not received ART in Hunan province, China, were enrolled in the study. Plasma samples were collected, RNA was extracted, two rounds of gene amplification were carried out with the in-house method, and subtype analysis and drug resistance analysis were carried out with relevant software. We found that the most prevalent subtypes of HIV-1 in Hunan Province are CRF_01AE (126/359, 35.1%) and CRF07_BC (85/359, 23.7%). The PDR rate among newly diagnosed HIV/AIDS patients was 10.0% (36/359). Among them, the drug resistance rates of protease inhibitors, nucleotide reverse transcriptase inhibitors, non-nucleotide reverse transcriptase inhibitors, and integrase inhibitors were 0.3% (1/359), 3.3% (12/359), 8.36% (30/359), and 0.6% (2/359), respectively. The distribution of HIV-1 subtypes in Hunan Province is diverse and complex, and the PDR rate has exceeded the low-level warning line set by the World Health Organization (<5%). Therefore, we should conduct pretreatment drug resistance assays to determine the optimal primary ART so that patients can obtain better antiretroviral treatment outcomes and transmission of drug-resistant strains in the population can be blocked.
科研通智能强力驱动
Strongly Powered by AbleSci AI